Released Mar 13, 2025, after the close
10-K filed Mar 13, 2025, 72 days after period end · 0000950170-25-038884
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$14.81M$14.81M derived−87.0% vs Q4 2023+73.8% vs Q3 2024
Net Income-$72.44M-$72.44M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$65,258,000N/M
Operating Cash Flowderived-$71,738,000N/M
Margins · derived
Operating margin-440.7%−478.6 pt vs Q4 2023
Net margin-489.2%−516.5 pt vs Q4 2023
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $14.81M | $113.72M | $8.63M | $10.65M |
| Net Income | -$72.44M | $31.07M | -$34.59M | -$38.13M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR